Adjuvant chemotherapy to definitive treatment of prostate cancer.
Even though surgery and/or radiation has been the treatment of choice of early carcinoma of the prostate, there is conclusive evidence that tumor may recur in a certain number of patients at the primary site and/or at a distant location. The only way to achieve a complete cure in these patients with localized cancer appears to be by addition of relatively safe, effective chemotherapeutic agents. Estracyt and/or Cytoxan appear to be such agents. These two drugs showed definite activity  in the treatment of patients with advanced prostatic carcinoma. Chemotherapeutic agents appear effective as adjuvant in the treatment of other solid tumors. It is worthwhile that this modality of treatment be tried in patients with early, curable prostatic carcinoma.
D000970:Antineoplastic Agents; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D011897:Random Allocation
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D003520:Cyclophosphamide